glp-1 drugs and gastroparesis New data links agonists for weight loss with higher risk for pancreatitis, GI events GLP-1 Drugs and Gastroparesis: What

GLP-1 receptor agonists not only reduce appetite but also reshape food preferences, shedding light on the neural mechanisms underlying compulsive consumption and offering potential therapeutic avenues for metabolic and behavioral disorders

This is important especially in the pediatric population, to have close follow-up with dietitian

& Csoka, I

Keeping a finger on the pulse of this data will help leaders measure the programs ROI while ensuring employees receive the care and support they need. A benefits landscape in flux This is shaping up to be a pivotal year for the GLP-1 drug class, says Campbell, as a number of macro trends will influence the landscape in which HR and benefits leaders are considering plan design and implementation

For example, some programs have demonstrated that members who dont take GLP-1s but do engage in intensive lifestyle modification still achieve significant weight loss (around 9% loss after one year, according to data from one of our partners)